Cargando…

Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer

SIMPLE SUMMARY: Paclitaxel-based chemotherapy is the standard front-line therapy for advanced or metastatic endometrial cancer. However, paclitaxel resistance eternally develops. Based on the high prevalence of PIK3CA mutation, reaching 50%, in endometrial cancer, we preclinically investigated the e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jeong, Yeong Gyu, Katuwal, Nar Bahadur, Kang, Min Sil, Ghosh, Mithun, Hong, Sa Deok, Park, Seong Min, Kim, Seul-Gi, Kim, Tae Hoen, Moon, Yong Wha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571568/ https://www.ncbi.nlm.nih.gov/pubmed/37835582 http://dx.doi.org/10.3390/cancers15194887

Ejemplares similares

Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer
por: Katuwal, Nar Bahadur, et al.
Publicado: (2023)

Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase
por: Pandey, Kamal, et al.
Publicado: (2022)

Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer
por: Hur, Jin, et al.
Publicado: (2021)

Deregulated Immune Pathway Associated with Palbociclib Resistance in Preclinical Breast Cancer Models: Integrative Genomics and Transcriptomics
por: Pandey, Kamal, et al.
Publicado: (2021)

Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma
por: Mittal, Sonam, et al.
Publicado: (2023)

miR-150 enhances apoptotic and anti-tumor effects of paclitaxel in paclitaxel-resistant ovarian cancer cells by targeting Notch3
por: Kim, Tae Hoen, et al.
Publicado: (2017)

Cellular and Molecular Effects of Eribulin in Preclinical Models of Hematologic Neoplasms
por: Vicari, Hugo Passos, et al.
Publicado: (2022)

PIK3CA Mutations in Hepatocellular Carcinoma in Korea
por: Kim, Heesue, et al.
Publicado: (2013)

Inhibition of Phosphatidylinositol 3-kinase (PI3K) Signaling Synergistically Potentiates Antitumor Efficacy of Paclitaxel and Overcomes Paclitaxel-Mediated Resistance in Cervical Cancer
por: Liu, Jing Jing, et al.
Publicado: (2019)

PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data
por: Zardavas, Dimitrios, et al.
Publicado: (2014)

Eribulin and Paclitaxel Differentially Alter Extracellular Vesicles and Their Cargo from Triple-Negative Breast Cancer Cells
por: Pederson, Petra J., et al.
Publicado: (2021)

Targeting PIK3CG in Combination with Paclitaxel as a Potential Therapeutic Regimen in Claudin-Low Breast Cancer
por: Chang, Jun, et al.
Publicado: (2020)

Malignant Adenomyoepithelioma of the Breast and Responsiveness to Eribulin
por: Lee, Suee, et al.
Publicado: (2015)

Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma
por: Sampson, Valerie B., et al.
Publicado: (2016)

Eribulin drug review
por: Shetty, Nishitha, et al.
Publicado: (2014)

Eribulin in Cancer Treatment
por: Swami, Umang, et al.
Publicado: (2015)

Carcinogenesis of PIK3CA
por: German, Sidra, et al.
Publicado: (2013)

CapG promotes resistance to paclitaxel in breast cancer through transactivation of PIK3R1/P50
por: Chi, Yayun, et al.
Publicado: (2019)

Targeting PIK3CG in Combination with Paclitaxel as a Potential Therapeutic Regimen in Claudin-Low Breast Cancer [Corrigendum]
Publicado: (2020)

Class I Phosphoinositide 3-Kinase PIK3CA/p110α and PIK3CB/p110β Isoforms in Endometrial Cancer
por: Mazloumi Gavgani, Fatemeh, et al.
Publicado: (2018)

Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models
por: Funahashi, Yasuhiro, et al.
Publicado: (2014)

Correlation of PIK3CA mutation with programmed death ligand-1 (PD-L1) expression and their clinicopathological significance in colorectal cancer
por: Ahn, Ae Ri, et al.
Publicado: (2021)

Preclinical platform for long-term evaluation of immuno-oncology drugs using hCD34+ humanized mouse model
por: Park, Nahee, et al.
Publicado: (2020)

Expression of PIK3CA, PTEN mRNA and PIK3CA mutations in primary breast cancer: association with lymph node metastases
por: Palimaru, Irina, et al.
Publicado: (2013)

Targeting β-catenin overcomes MEK inhibition resistance in colon cancer with KRAS and PIK3CA mutations
por: Moon, Jai-Hee, et al.
Publicado: (2019)

PIK3CA in Colorectal Cancer
por: Cathomas, Gieri
Publicado: (2014)

Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients
por: Chen, Li, et al.
Publicado: (2018)

Pan-cancer analysis on the role of PIK3R1 and PIK3R2 in human tumors
por: Liu, Yane, et al.
Publicado: (2022)

NSAIDs Overcome PIK3CA Mutation-Mediated Resistance to EGFR Inhibition in Head and Neck Cancer Preclinical Models
por: Li, Hua, et al.
Publicado: (2022)

Activation of WNT/β‐catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations
por: Park, Ye‐Lim, et al.
Publicado: (2018)

Prognostic implications of PIK3CA amplification in curatively resected liposarcoma
por: Kim, Joo Hoon, et al.
Publicado: (2016)

Cezanne promoted autophagy through PIK3C3 stabilization and PIK3C2A transcription in lung adenocarcinoma
por: Wang, Yadong, et al.
Publicado: (2023)

Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells
por: Weber, Genevieve L., et al.
Publicado: (2011)

Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer
por: Jung, Ki Sun, et al.
Publicado: (2017)

A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma
por: Zhu, Jingyu, et al.
Publicado: (2014)

Mutations of PIK3CA in gastric adenocarcinoma
por: Li, Vivian Sze Wing, et al.
Publicado: (2005)

Mutations in PIK3CA are infrequent in neuroblastoma
por: Dam, Vincent, et al.
Publicado: (2006)

PIK3CA-mutations in breast cancer
por: Reinhardt, Kristin, et al.
Publicado: (2022)

Pik3ip1 Modulates Cardiac Hypertrophy by Inhibiting PI3K Pathway
por: Song, Hong Ki, et al.
Publicado: (2015)

Efficacy of Eribulin in Soft Tissue Sarcomas
por: Phillips, Edward, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fo99i293t8op0jt3e03in2st8a